Treatment.com AI Inc. Completes Successful Private Placement
Recently, Treatment.com AI Inc. (CSE: TRUE; OTC: TREIF; FFA: 939) shared exciting news about a significant milestone in its funding journey. The company has successfully closed an over-subscribed non-brokered private placement of special warrants and units, totaling an impressive $1,954,074. This move comes on the heels of their earlier announcement regarding this financing initiative.
Details of the Closure
The private placement involved 2,138,766 special warrants priced at $0.75 each, which raised around $1,604,074.50. Additionally, the placement included 466,666 units at the same price, generating gross proceeds of $349,999.50. Each unit comprises a common share alongside a half-share purchase warrant. The warrants provide an opportunity to purchase an additional share at $1.00 for a period of two years.
Conversion Insights
Interestingly, the special warrants will automatically convert into units at no further expense to the holders. This conversion happens either three business days following the submission of a prospectus supplement or after four months and one day from their issue date. Importantly, holders cannot exercise the special warrants before this conversion date, ensuring clarity for their investors.
Leadership's Vision
Dr. Essam Hamza, CEO of Treatment.com AI Inc., expressed gratitude toward the investors, noting their strong support for the financing. He remarked on how this successful fundraising will significantly bolster the company's growth strategies in the upcoming year. The enthusiasm from the investors signifies trust in Treatment's vision of leveraging AI to enhance healthcare delivery.
Use of Proceeds
The capital raised through this offering will predominantly serve for working capital purposes, fueling the company's operational efficiency and growth initiatives. It's noteworthy that both the units issued and the broker warrants will adhere to a statutory hold period, ensuring compliance with securities legislation.
Investor Assurance
While Treatment.com AI Inc. is making strides, they have made it clear that securities from this offering have not been registered under the U.S. Securities Act and cannot be traded without proper registration or exemptions. This is a safeguard for investors, ensuring all legal regulations are followed adequately.
About Treatment.com AI Inc.
Treatment.com AI Inc. is at the forefront of integrating artificial intelligence within the healthcare sector. By fostering enhancements in clinical practices, the company aims to address prevalent inefficiencies within the field. Leveraging input from a wide array of healthcare professionals, Treatment has developed a robust AI engine known as the Global Library of Medicine (GLM). This resource boasts over 10,000 expert medical reviews that facilitate healthcare professionals in delivering quality care efficiently.
The Global Library of Medicine
The GLM serves as an extensive platform offering clinical insights, recommended lab tests, and necessary billing codes. It’s designed to alleviate administrative burdens from healthcare professionals, allowing them to prioritize direct patient interaction. Moreover, Treatment is committed to ensuring that underserved communities have access to quality healthcare, further underlining their dedication to improving health outcomes across various demographics.
Contact Information
If you’re looking to learn more about Treatment.com AI and its initiatives, you may reach out through the following contact methods:
Dr. Essam Hamza, CEO
ehamza@treatment.com
Call: +1 (612) 788-8900 / Toll-Free USA/Canada: +1 (888) 788-8955
Additionally, for media inquiries, you can contact media@treatment.com.
Frequently Asked Questions
What is Treatment.com AI Inc. focused on?
Treatment.com AI Inc. is dedicated to improving healthcare through the integration of artificial intelligence, enhancing clinical practices, and addressing inefficiencies.
How much capital did Treatment.com raise recently?
The company successfully closed a private placement raising approximately $1,954,074.
What will the proceeds from the offering be used for?
The proceeds will primarily be directed toward working capital and growth initiatives to bolster the company's operations.
What are special warrants and units in this context?
Each unit consists of one common share and one-half of a share purchase warrant, while special warrants convert into units automatically under certain conditions.
How can I reach Treatment.com AI Inc. for inquiries?
Interested parties can contact Dr. Essam Hamza via email at ehamza@treatment.com or call +1 (612) 788-8900 for more information.
